Cited by 388Treatment of Major DepressionNerve injury and regenerationTryptophan and brain disorders

Brain‐derived neurotrophic factor as a biomarker for mood disorders: An historical overview and future directions

Open access
Hashimoto, Kenji·2010·Psychiatry and Clinical Neurosciences

Abstract

Mood disorders, such as major depressive disorder (MDD) and bipolar disorder (BPD), are the most prevalent psychiatric conditions, and are also among the most severe and debilitating. However, the precise neurobiology underlying these disorders is currently unknown. One way to combat these disorders is to discover novel biomarkers for them. The development of such biomarkers will aid both in the diagnosis of mood disorders and in the development of effective psychiatric medications to treat them. A number of preclinical studies have suggested that the brain‐derived neurotrophic factor (BDNF) plays an important role in the pathophysiology of MDD. In 2003, we reported that serum levels of BDNF in antidepressant‐naive patients with MDD were significantly lower than those of patients medicated with antidepressants and normal controls, and that serum BDNF levels were negatively correlated with the severity of depression. Additionally, we found that decreased serum levels of BDNF in antidepressant‐naive patients recovered to normal levels associated with the recovery of depression after treatment with antidepressant medication. This review article will provide an historical overview of the role played by BDNF in the pathophysiology of mood disorders and in the mechanism of action of therapeutic agents. Particular focus will be given to the potential use of BDNF as a biomarker for mood disorders. BDNF is initially synthesized as a precursor protein proBDNF, and then proBDNF is proteolytically cleaved to the mature BDNF. Finally, future perspectives on the use of proBDNF as a novel biomarker for mood disorders will be discussed.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1440-1819.2010.02113.x

Cites

178 of 178 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Part of this paper’s reference list could not be split into single entries.

Flagged first, then by citations

Research works printed but not linked: 4

  1. Reichardt LF. Neurotrophin-regulated signaling path- ways. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2006; 361: 1545-1564.
  2. U.S.A. 1999; 96: 15239-15244.
  3. Hariri AR, Goldberg TE, Mattay VS et al. Brain-derived neurotrophic factor val66met polymorphism affects human memory-related hippocampal activity and pre- dicts memory performance. J. Neurosci. 2003; 23: 6690- 6694.
  4. Sklar P. Linkage analysis in psychiatric disorders: The emerging picture. Annu. Rev. Genomics Hum. Genet. 2003; 3: 371-413.

Cited by

Sorted by citations

Authors
Hashimoto, K.
Affiliations
Chiba University (JP)
Corresponding author
Hashimoto, Kenji
Venue
Psychiatry and Clinical Neurosciences
Publisher
Wiley
Published
2010-07-23
Volume
64
Issue
4
Pages
341-357
ISSN
  • 1323-1316 (ISSN-L)
  • 1440-1819
OpenAlex
W1659530875
Cited by
388
References
178
Citations by year
2026: 8 · 2025: 11 · 2024: 15 · 2023: 15 · 2022: 21 · 2021: 25 · 2020: 22 · 2019: 19 · 2018: 21 · 2017: 27 · 2016: 37 · 2015: 38 · 2014: 31 · 2013: 34 · 2012: 33
FWCI
3.47
Type
journal article
Language
en
Open access
Locations
  • Psychiatry and Clinical Neurosciences (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Nerve injury and regeneration
  • Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
Keywords
brain-derived neurotrophic factor, mood disorders, major depressive disorder, bipolar disorder, serum BDNF, biomarkers, antidepressant response, depression severity, proBDNF
MeSH terms
Animals, Bipolar Disorder, Major Depressive Disorder, Humans, Polymorphism, Genetic, Protein Precursors, Biomarkers, Brain-Derived Neurotrophic Factor, Mood Disorders, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review